Which study uses a dosing schedule of monthly injections for 3 months and then three consecutive monthly injections as needed?

The IVAN study, which stands for the “Intravitreous Bevacizumab for Neovascular Age-related Macular Degeneration,” utilized a dosing schedule characterized by monthly injections for the first three months, followed by a flexible approach whereby injections were administered as needed for the next three consecutive months. This regimen allowed for an initial intensive treatment phase to stabilize vision, after which the frequency of treatments was adapted based on the individual patient's response and the severity of their condition.

This design is significant as it supports the concept of tailoring treatment to patient needs over time, aligning treatment intensity with clinical response. Such a strategy can potentially minimize the burden of frequent injections while ensuring effective management of neovascular age-related macular degeneration, which is essential for preserving vision. This tailored approach distinguishes the IVAN study from those with more rigid dosing protocols, emphasizing its focus on patient-centered treatment.